Tango Therapeutics Inc. (TNGX)
1.27
-0.10 (-7.30%)
At close: Apr 03, 2025, 3:59 PM
1.27
-0.39%
After-hours: Apr 03, 2025, 04:05 PM EDT
Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.
Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer.
The company was founded in 2017 and is based in Cambridge, Massachusetts.
Tango Therapeutics Inc.
| Country | United States |
| IPO Date | Sep 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Dr. Barbara L. Weber M.D. |
Contact Details
Address: 100 Binney Street Cambridge, Massachusetts United States | |
| Website | https://www.tangotx.com |
Stock Details
| Ticker Symbol | TNGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819133 |
| CUSIP Number | 87583X109 |
| ISIN Number | US87583X1090 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barbara L. Weber M.D. | President, Chief Executive Officer & Director |
| Douglas J. Barry Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary |
| Timothy Redfern | Chief Financial Officer |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research & Development |
| Dr. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Michael Palmieri Ph.D. | Head of Technical Operations |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board |
| Elizabeth Pingpank Hickin | Vice President of IR & Corporate Communications |
| Jannik N. Andersen Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | S-8 | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 06, 2025 | 4 | Filing |
| Feb 06, 2025 | 4 | Filing |
| Feb 06, 2025 | 4 | Filing |
| Feb 06, 2025 | 4 | Filing |
| Feb 05, 2025 | 4 | Filing |
| Feb 05, 2025 | 4 | Filing |